May 2, 2018 Alison Moore Re: Employment Letter of Agreement (“Agreement”) Dear Alison:Employment Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Allogene Therapeutics, Inc. (“Allogene” or the “Company”) is pleased to offer you employment on the following terms and conditions.
Re: Employment Letter of Agreement (“Agreement”)Employment Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
Allogene Therapeutics, Inc. (“Allogene” or the “Company”) is pleased to offer you employment on the following terms and conditions.
ASSET CONTRIBUTION AGREEMENT BY AND BETWEEN PFIZER INC. AND ALLOGENE THERAPEUTICS, INC. Dated as of April 2, 2018Asset Contribution Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Asset Contribution Agreement (this “Agreement”) is entered into as of April 2, 2018 (the “Effective Date”), by and between Pfizer Inc., a Delaware corporation (“Pfizer”), and Allogene Therapeutics, Inc., a Delaware corporation (“NewCo”).
TRANSITION SERVICES AGREEMENTTransition Services Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This TRANSITION SERVICES AGREEMENT (this “Agreement”) is made and entered into as of the 6th day of April, 2018 (the “Effective Date”) between Pfizer, Inc., a Delaware corporation (“Pfizer”), and Allogene Therapeutics, Inc., a Delaware corporation (“NewCo”) (each, a “Party” and together, the “Parties”).
April 2, 2018 Allogene Therapeutics, Inc.Asset Contribution Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)
RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND CELLECTIS SA JUNE 17, 2014Research Collaboration and License Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of June 17, 2014 (the “Effective Date”), by and among Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 235 East 42nd Street, New York, New York, 10017 United States (“Pfizer”) and Cellectis SA, a corporation organized and existing under the laws of France and having a place of business at 8 rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Pfizer and Cellectis may each be referred to herein individually as a “Party” and collectively as the “Parties.”
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 14th, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 6, 2018 by and among Allogene Therapeutics, Inc. a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
